SeaStar Medical Holding (ICU) 10-Q 14 May 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2024	Apr. 30, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Entity Registrant Name	SEASTAR MEDICAL HOLDING CORPORATION
Entity Central Index Key	0001831868
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-39927
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3681132
Entity Address, Address Line One	3513 Brighton Blvd.,
Entity Address, Address Line Two	Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80216
City Area Code	844
Local Phone Number	427-8100
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		75,419,458
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ICU
Security Exchange Name	NASDAQ
Redeemable Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share
Trading Symbol	ICUCW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash	$ 5,019	$ 176
Prepaid expenses	1,518	2,132
Total current assets	6,537	2,308
Other assets	1,203	1,205
Total assets	7,740	3,513
Current liabilities
Accounts payable	3,879	4,372
Accrued expenses	1,544	1,523
Contingent upfront payment for license agreement	100	100
Notes payable, net of deferred financing costs	357	565
Convertible notes, current portion	1,135	4,179
Liability classified warrants	2,633	2,307
Total current liabilities	9,648	13,046
Notes payable, net of deferred financing costs	2,565	4,143
Convertible notes, net of current portion	0	194
Total liabilities	12,213	17,383
Commitments and contingencies (Note 9)
Stockholders' deficit
Preferred stock - $0.0001 par value, 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock - $0.0001 par value per share; 500,000,000 shares authorized; 75,419,458 and 47,615,285 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	8	5
Additional paid-in capital	122,950	100,859
Accumulated deficit	(127,431)	(114,734)
Total stockholders' deficit	(4,473)	(13,870)
Total liabilities and stockholders' deficit	$ 7,740	$ 3,513

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	75,419,458	47,615,285
Common stock, shares outstanding	75,419,458	47,615,285

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 1,697	$ 1,730
General and administrative	2,253	2,851
Total operating expenses	3,950	4,581
Loss from operations	(3,950)	(4,581)
Other income (expense)
Interest expense	(143)	(433)
Change in fair value of convertible notes	(5,758)	100
Change in fair value of warrants liability	(2,846)	36
Change in the fair value of the forward purchase agreement derivative liability	0	(2,218)
Total other income (expense), net	(8,747)	(2,515)
Loss before provision for income taxes	(12,697)	(7,096)
Provision for income taxes	0	0
Net loss	$ (12,697)	$ (7,096)
Net loss per share:
Net loss per share of common stock, basic	$ (0.19)	$ (0.54)
Net loss per share of common stock, diluted	$ (0.19)	$ (0.54)
Weighted-average shares outstanding - basic	67,106,081	13,025,852
Weighted-average shares outstanding - diluted	67,106,081	13,025,852

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2022	$ (20,762)	$ 1	$ 67,739	$ (88,502)
Beginning Balances (in shares) at Dec. 31, 2022		12,699,668
Issuance of shares - equity line of credit, Shares		378,006
Issuance of shares - equity line of credit	1,108		1,108
Issuance of shares - commitment fee for equity line of credit, Shares		218,842
Issuance of shares - commitment fee for equity line of credit	1,000		1,000
Issuance of shares - prepaid forward contracts (As restated)	1,870		1,870
Stock-based compensation	505		505
Net loss	(7,096)			(7,096)
Ending Balance at Mar. 31, 2023	(23,375)	$ 1	72,222	(95,598)
Ending Balances (in shares) at Mar. 31, 2023		13,296,516
Beginning Balance at Dec. 31, 2023	(13,870)	$ 5	100,859	(114,734)
Beginning Balances (in shares) at Dec. 31, 2023		47,615,285
Issuance of shares - conversion of convertible notes, Shares		12,697,792
Issuance of shares - conversion of convertible notes	9,390	$ 1	9,389
Issuance of shares - exercise of warrants, Shares		8,801,836
Issuance of shares - exercise of warrants	3,960	$ 1	3,959
Issuance of shares - equity offering, net of issue costs, Shares		6,304,545
Issuance of shares - equity offering, net of issue costs	8,310	$ 1	8,309
Stock-based compensation	434		434
Net loss	(12,697)			(12,697)
Ending Balance at Mar. 31, 2024	$ (4,473)	$ 8	$ 122,950	$ (127,431)
Ending Balances (in shares) at Mar. 31, 2024		75,419,458

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (12,697)	$ (7,096)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of deferred financing costs	27	4
Change in fair value of convertible notes (issued, converted and outstanding)	5,758	2,218
Change in fair value of forward purchase agreement derivative liability	0	(100)
Change in fair value of liability classified warrants (exercised and outstanding)	2,846	(36)
Stock-based compensation	434	505
Changes in operating assets and liabilities
Other receivables	0	12
Prepaid expenses	614	318
Other assets	2	0
Accounts payable	(493)	1,095
Accrued expenses	21	0
Other liabilities	0	786
Net cash used in operating activities	(3,488)	(2,294)
Cash flows from financing activities
Proceeds from issuance of convertible notes	979	3,000
Payment of convertible notes	0	(10)
Proceeds from issuance of shares	4,543	1,108
Proceeds from exercise of convertible note warrants	853	0
Proceeds of Pre-Funded warrants	3,769	0
Payment of commitment fee - equity line of credit	0	(500)
Proceeds from sale of recycled shares	0	1,870
Proceeds from notes payable	0	100
Payment of notes payable	(1,813)	(2,596)
Net cash provided by financing activities	8,331	2,972
Net increase in cash	4,843	678
Cash, beginning of period	176	47	$ 47
Cash, end of period	5,019	725	$ 176
Supplemental disclosure of cash flow information
Cash paid for interest	0	508
Exercise of pre-funded warrants	3,106	0
Shares issued as payment of convertible notes	9,387	0
Issuance of convertible note warrants	$ 586	$ 500

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (12,697)	$ (7,096)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1. D e scription of Business Organization and description of business SeaStar Medical Holding Corporation, a Delaware corporation ("SeaStar", "we") and its wholly owned subsidiary, SeaStar Medical, Inc., are collectively referred to as the "Company". SeaStar Medical, Inc. was incorporated as a Delaware corporation in June 2007, and it is headquartered in Denver, Colorado. The Company is principally engaged in the research, development, and commercialization of a platform medical device technology designed to modulate inflammation in various patient populations. The primary target of this technology is for the treatment of acute kidney injuries. The Company is in the pre-revenue stage focused on product development. On October 28, 2022, LMF Merger Sub, Inc., a wholly owned subsidiary of LMF Acquisition Opportunities, Inc., (“LMAO”) merged with and into SeaStar Medical, Inc. (the "Business Combination"), with SeaStar Medical, Inc. surviving the Business Combination as a wholly owned subsidiary of LMAO. Following the consummation of the Business Combination, LMAO was renamed to "SeaStar Medical Holding Corporation." Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC") for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three months ended March 31, 2024, are not necessarily indicative of the results to be expected for the year ended December 31, 2024, or for any future annual or interim period. The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the related notes for the year ended December 31, 2023. There have been no material changes in our significant accounting policies as described in our Annual Report on Form 10-K for the year ended December 31, 2023. The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company's wholly owned subsidiary, SeaStar Medical, Inc. All significant intercompany transactions have been eliminated in consolidation. Segment information The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. Liquidity and going concern As of March 31, 2024, the Company has an accumulated deficit of $ 127.4 million and cash of $ 5.0 million. We do not believe that will be sufficient to enable us to fund our operations, including clinical trial expenses and capital expenditure requirements for at least 12 months from the issuance of these unaudited interim condensed consolidated financial statements. We believe that these conditions raise substantial doubt about our ability to continue as a going concern. Our need for additional capital will depend in part on the scope and costs of our development activities. To date, we have not generated any revenue from the sales of commercialized products. Our ability to generate product revenue will depend on the successful development and eventual commercialization of our product. Until such time, if ever, we expect to finance our operations through the sale of equity or debt, borrowing under credit facilities, or through potential collaborations, other strategic transactions or government and other grants. Adequate capital may not be available to us when needed or on acceptable terms. Risks and uncertainties The Company is subject to risks common to early-stage companies in the medical technology industry including, but not limited to, new medical and technological innovations, dependence on key personnel, protection of proprietary technology, and product liability. There can be no assurance that the Company's products or services will be accepted in the marketplace, nor can there be any assurance that any future products or services can be developed or deployed at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all. These factors could have a materially adverse effect on the Company's future financial results, financial position and cash flows.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the liability classified warrants, prepaid forward purchase agreement derivative liability, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time. Concentrations of credit risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows. Fair value of financial instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statement of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to fair value Warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants each reporting period is recorded to the change in fair value of warrants liability in the consolidated statement of operations. Emerging growth company status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Recently issued accounting standards In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures.

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Accrued Expenses	Note 3. Accrued Expenses Accrued expenses consisted of the following amounts as of March 31, 2024 and December 31, 2023: ($ in thousands) March 31, December 31, Accrued bonus $ 671 $ 501 Accrued director compensation 519 427 Accrued research and development 308 507 Accrued legal — 43 Accrued interest 29 19 Other 17 26 Total accrued expenses $ 1,544 $ 1,523

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2024
Notes Payable [Abstract]
Notes Payable	Note 4. Notes Payable Notes payable activity was as follows for the three month period ended March 31, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ ( 52 ) Payments ( 296 ) ( 1,128 ) ( 181 ) ( 208 ) — Amortization of costs — — — — 27 Balance as of March 31, 2024 $ — $ — $ 2,590 $ 357 $ ( 25 ) Future maturities of principal repayment of the notes payable as of March 31, 2024 are as follows: ($ in thousands) 2024 (remaining) $ 357 2025 2,590 $ 2,947 Senior Secured LMFA Note Payable The company entered into a senior secured note with LMFA in September 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during Q1 2024. Senior Secured LMFAO Note Payable The company entered into a senior secured note with LMFAO in October 2022. The interest rate on the loan was 7.0 % and was to mature on March 27, 2025 . The Company paid this note in full during Q1 2024. Unsecured Maxim Note Payable In October 2022, the Company entered into an unsecured promissory note with Maxim, for an aggregate principal amount of $ 4.2 million. The interest rate on the note is 7 % and matures on May 8, 2025 . Insurance Financing In October 2023, the Company entered into a financing arrangement with a lender to finance a portion of the annual premium of an insurance policy in the amount of $ 0.7 million. The Company will pay the remaining five monthly installments of principal and interest with the last payment being made in August 2024 .

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Convertible Notes	Note 5. Convertible Notes The activity for the convertible notes is disclosed in the table below for the period ended March 31, 2024. See our Annual Report on Form 10-K for the year-ended for December 31, 2023, for all other details relating to the Investor D convertible notes issued prior to December 31, 2023. During the quarter-ended March 31, 2024, the Company entered into two additional Investor D note issuances: The Company completed Additional Closings related to the Second Amendment to the Investor D SPA on January 12, 2024 and January 24, 2024, issuing notes in principal amounts of $ 0.3 million and $ 0.8 million, respectively, each at 7.00 % per annum (the "Fifth Investor D Note" and "Sixth Investor D Note", collectively called the "2024 Investor D Notes"). The 2024 Investor D Notes mature on April 12, 2025 and April 24, 2025 , respectively. The 2024 Investor D Notes have an initial conversion price of $ 0.56 per share and are convertible into shares of the Company's common stock, par value $ 0.0001 (the "common stock"), beginning on the earlier of June 11, 2024 (or earlier upon mutual written agreement of the Company and the purchaser), or the date of an event of default, as defined in the note. The Company also issued warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share, and an additional warrants to purchase up to 131,927 and 395,781 shares of common stock, respectively, with an exercise price of $ 0.56 per share. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/Loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 125 ) ( 607 ) ( 2,381 ) ( 9,497 ) (Gain)/Loss on reporting period remeasurement — — — — 361 — — 361 Balance as of March 31, 2024 $ — — $ — $ — $ 1,135 $ — $ — 1,135 Future maturities of principal repayment of convertible Notes as of March 31, 2024, was as follows: ($ in thousands) 2024 (remaining) $ — 2025 1,135 $ 1,135 On January 30, 2024, the institutional investor agreed to waive its Optional Redemption Rights and any event of default that may arise thereunder with respect to this offering and suspend the Optional Redemption Rights for a period of sixty ( 60 ) days following the closing of this offering (the “Suspension Period”), and the Company granted the institutional investor a right to redeem all or a portion of the then outstanding Conversion Amount (as defined in the Note Documents) within three (3) trading days after the Suspension Period at an amount equal to 200 % of the Conversion Amount. During the quarter-ended March 31, 2024, the institutional investor converted approximately $ 3.3 million (face value) of outstanding debt, by converting the outstanding debt into approximately $ 9.5 million of the Company's common stock. As of March 31, 2024, the Company still owed the institutional investor approximately $ 1.0 million (face value) in convertible debt, with a fair value of approximately $ 1.1 million. The Company incurred a loss of approximately $ 5.8 million as a result of the following: (i) $ 4.7 million loss on conversion into equity as a result of the difference between the fair value of the convertible notes being converted and the equity being delivered, (ii) $ 0.7 million losses on issuance of the Investor D convertible notes issued during the three-months ended March 31, 2024, as a result of the combination of the fair value of detachable warrants issued in conjunction to the Investor D Notes issues during the three-months ended March 31, 2024, and the excess fair value over the proceeds received for the Investor D convertible notes issues during the three-months ended March 31, 2024, and (iii) $ 0.4 million loss on the change in fair value of those Investor D convertible notes still outstanding as of March 31, 2024.

Equity Transactions

Equity Transactions	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity Note [Abstract]
Equity Transactions	Note 6. Equity Transactions On January 26, 2024, the Company entered into a Securities Purchase Agreement with a single institutional investor, pursuant to which the Company issued to the Purchaser (the "Q1 2024 SPA"), (i) in a registered direct offering, 6,304,545 shares of the Company’s common stock, par value $ 0.0001 per share, and pre-funded warrants to purchase 4,536,216 shares of Common Stock with an exercise price of $ 0.0001 per share, and (ii) in a concurrent private placement, series A warrants to purchase 10,840,761 shares of common stock (the "Series A Common Warrants") and series B warrants to purchase 5,420,381 shares of common stock each with an exercise price of $ 0.8302 (the "Series B Common Warrants" and together with the Series A Common Warrants, the "Investor E Warrants". Such registered direct offering and concurrent private placement are referred to herein as the “Transactions.” The Company received aggregate gross proceeds from the Transactions of approximately $ 9.0 million, before deducting fees to the Placement Agent and other estimated offering expenses payable by the Company. The Shares were declared effective on December 22, 2023. The Investor E Warrants will be exercisable commencing on the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants. The Series A Common Warrants will expire on the fifth anniversary of the Stockholder Approval Date and the Series B Common Warrants will expire on the 12 month anniversary of the Stockholder Approval Date. The Pre-Funded Warrants will not expire and will be exercisable commencing on January 26, 2024, and at any time until all of the Pre-Funded Warrants are exercised in full. All Pre-Funded Warrants were exercised during the first quarter ended March 31, 2024. The Company paid approximately $ 0.7 million in fees to the Placement Agent and issued 542,038 warrants (the "PA Warrants") to purchase shares of the Company's common stock, with a fair value of approximately $ 0.3 million at issuance. The exercise price of these warrants is $ 0.9132 and the warrants became exercisable on January 30, 2024 , expiring one year after the grant date. Tumin Equity Line of Credit During the year ended December 31, 2023, the Company sold 6,500,000 shares of common stock to Tumim for proceeds of approximately $ 4.7 million as part of the Tumin Equity Line of Credit (see the Company's Annual Report on Form 10-K for the year-ended December 31, 2023, for additional information on the structure and purpose). As of December 31, 2023, approximately $ 95.3 million was available to draw. In February 2024, the Company and Tumim agreed to terminate the Purchase Agreement.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2024
Warrants and Rights Note Disclosure [Abstract]
Warrants	Note 7. Warrants Warrants Issued in FY 2024 As discussed in Note 7, as part of the Q1 2024 SPA, the Company issued on January 26, 2024 the following warrants to purchase the Company's common stock: • Pre-Funded Warrants - warrants to purchase 4,536,216 shares of common stock with an exercise price of $ 0.0001 . The Pre-Funded Warrants had no expiration date and were exercisable commencing on the date of issuance and at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants were exercised in full during the first quarter-ended March 31, 2024 • Series A and Series B Warrants - in a concurrent private placement, Series A Common Warrants to purchase 10,840,761 shares of Common Stock and Series B Common Warrants to purchase 5,420,381 shares of common stock each with an exercise price of $ 0.8302 . • Investor E Warrants will be exercisable commencing on the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the Investor E Warrants. The Series A Common Warrants will expire on the fifth anniversary of the Stockholder Approval Date and the Series B Common Warrants will expire on the 12-month anniversary of the Stockholder Approval Date. Maxim Group LLC acted as the placement agent in connection with the Transactions pursuant to the Placement Agency Agreement, dated January 26, 2024, by and between the Company and the Placement Agent. The Placement Agent will receive warrants to purchase common stock covering a number of shares equal to 5 % of the total number of shares of common stock sold in the Transactions. The PA Warrants will be exercisable commencing six months after the Closing and will expire five years after such date. The PA Warrants are exercisable at a price equal to 110.0 % of the offering price in connection with the placement. In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity , the Company determined the Investor E and PA Warrants meet the conditions for equity classification, and should be carried on the consolidated balance sheets as a component of stockholders equity (deficit). The initial fair value of the convertible note warrants was determined using a Black-Scholes option pricing model, which considers variables such as estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is five years. The Company had the following warrants outstanding at March 31, 2024 and December 31, 2023: March 31, December 31, Liability Classified Warrants Investor D Warrants 3,158,086 6,368,289 Private Placement Warrants 5,738,000 5,738,000 PIPE Investor Warrants 500,000 500,000 Subtotal 9,396,086 12,606,289 Equity Classified Warrants Investor E Warrants 16,261,142 — Placement agent Warrants 542,038 — Public Stockholders' Warrants 10,550,000 10,550,000 Legacy Warrants 48,914 48,914 Subtotal 27,402,094 10,598,914 Grand Total 36,798,180 23,205,203 The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of March 31, 2024 and December 31, 2023: March 31, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Investor D Warrants 3,158,086 $ 0.50 4.40 Private Placement Warrants 5,738,000 $ 11.50 3.57 PIPE Investor Warrants 500,000 $ 11.50 3.57 Equity Classified Warrants Investor E Warrants 16,261,142 $ 0.83 4.45 Placement Agent Warrants 542,038 $ 0.91 5.25 Public Stockholders' Warrants 10,550,000 $ 11.50 3.57 Legacy SeaStar Inc. Warrants 48,914 $ 10.00 2.13 December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Investor D Warrants 6,368,289 $ 0.50 4.65 Private Placement Warrants 5,738,000 $ 11.50 3.82 PIPE Investor Warrants 500,000 $ 11.50 3.82 Equity Classified Warrants Public Stockholders' Warrants 10,550,000 $ 11.50 3.82 Legacy SeaStar Inc. Warrants 48,914 $ 10.00 2.38 Below is the warrant activity for the period ended March, 31, 2024: Investor D Warrants Investor E Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 6,368,289 — - 5,738,000 500,000 10,550,000 48,914 Issuance 1,055,416 20,797,358 542,038 — — — — Exercised ( 4,265,619 ) ( 4,536,216 ) — — — — — Forfeited / cancelled — — — — — — — Outstanding as of March 31, 2024 3,158,086 16,261,142 542,038 5,738,000 500,000 10,550,000 48,914 During the quarter-ended March 31, 2024, the Company incurred $ 1.6 million from losses on exercises of certain Investor D Warrants, and a loss of approximately $ 1.2 million from the mark-to-market adjustment for all remaining liability classified warrants; which are required to be remeasured at fair value at each reporting period, including March 31, 2024. `

Stock-Based Compensation Awards

Stock-Based Compensation Awards	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Awards	Note 8. Stock-Based Compensation Awards The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Hi, I am hiring for my 9* logistics company. If interested, please send working stats and # of EE merits. Thank you! Three Months Ended March 31, ($ in thousands) 2024 2023 Research and development $ 119 $ 39 General and administrative 315 466 Total stock-based compensation $ 434 $ 505 Equity incentive plan - summary 2022 Omnibus Incentive Plan The Company's Board of Directors adopted, and the shareholders approved the 2022 Omnibus Incentive Plan to provide long-term incentive for its employees and non-employee service providers. The vesting of stock options is stated in each individual grant agreement, which is generally either one or four years . Options granted expire 10 years after the date of grant. 2019 Stock Incentive Plan The Company’s Board of Directors adopted the 2019 Stock Incentive Plan on February 25, 2019, to provide long-term incentive for its employees and non-employee service providers. The Stock Incentive Plan was terminated on October 28, 2022, and no further awards were granted under such plan. Equity incentive plan - stock options Option activity for the periods ended March 31, 2024, is as follows: 2022 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding at December 31, 2023 351,029 $ 1.84 $ — 9.1 Exercised — Issued — Forfeited / cancelled — Outstanding at March 31, 2024 351,029 $ 1.84 $ — 8.8 Vested and exercisable at March 31, 2024 - $ — $ — 8.8 2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding at December 31, 2023 244,792 $ 1.84 $ — 6.4 Exercised — Issued — Forfeited / cancelled — Outstanding at March 31, 2024 244,792 $ 1.84 $ — 6.2 Vested and exercisable at March 31, 2024 213,273 $ 1.84 $ — 6.2 Equity incentive plan - restricted stock units A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding at December 31, 2023 234,019 $ 1.47 Granted — Vested — Forfeited / cancelled — Outstanding at March 31, 2024 234,019 $ 1.47 2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding at December 31, 2023 92,442 $ 8.00 Exercised — Vested ( 19,689 ) Forfeited / cancelled — Outstanding at March 31, 2024 72,753 $ 8.00

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies License and distribution agreement On December 27, 2022, the Company entered into a license and distribution agreement (“License Agreement”) with a distributor, appointing the distributor as the exclusive distributor to promote, advertise, market, distribute and sell the Selective Cytopheretic Device (“SCD”) in the United States. The Company received an upfront payment of $ 0.1 million on January 3, 2023. Pursuant to the License Agreement, the Company received milestone payments in the amounts of approximately $ 0.5 million for obtaining a Humanitarian Device Approval ("HDE") from the Food and Drug Administration (the "FDA") and shall receive another milestone payment of approximately $ 0.4 million after the distributor sells the first sixty units to third parties. The term of the agreement is three years . The license agreement was amended in December 2023, removing the potential to require refund of the $ 0.1 million up-front payment from the Company to the distributor, while extending a certain milestone payment owed to the Company upon certain regulatory achievements. However, recognition for such relief from repayment of the deposit would be recognized over the remaining term of the agreement due to certain ongoing future obligations of the Company under the arrangement. Lease agreements The Company is part of a membership agreement for shared office space and can cancel at any time. Rent expense was approximately $ 8 thousand for the three months ended March 31, 2024 and 2023, respectively. Litigation Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. In connection with the Business Combination, LMAO proposed, for stockholder approval, various amendments to its Amended and Restated Certificate of Incorporation, which included among other things a proposal to increase the authorized shares of common stock. A purported stockholder sent a Stockholder Litigation Demand letter (the “Demand”) to the Board of Directors of LMAO alleging that the Delaware General Corporation Law required a separate class vote of the Class A common stockholders to increase the authorized shares of common stock. Following receipt of the Demand, the Company canceled and withdrew the proposal to increase the authorized shares of common stock. The stockholder’s counsel thereafter demanded that the Company pay counsel fees for the purported benefit conferred upon the Company’s shareholders by causing the Company to withdraw the allegedly invalid proposal to increase the authorized shares of common stock. The Company paid approximately $ 0.2 million for a legal settlement during the year ended December 31, 2023.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy: Level 1 – quoted prices in active markets for identical assets and liabilities. Level 2 – other significant observable inputs (including quoted prices for similar assets and liabilities, interest rate, credit risk, etc.). Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities). The fair value of the forward option on prepaid forward contracts, convertible notes, and the warrants liability is classified as Level 3 in the fair value hierarchy. Fair Value Measurement Hierarchy The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023, by level withing the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements at March 31, 2024 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 1,135 $ 1,135 Liability classified warrants — — 2,633 2,633 $ — $ — $ 3,768 $ 3,768 Fair Value Measurements at December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486 Summary of Level 3 Input Changes The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended March 31, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward Convertible Notes Liability Classified Warrants Balance December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle — — Shares issued upon conversion or exercise ( 4,100 ) ( 3,106 ) Changes in fair value 361 2,846 Balance March 31, 2024 $ 1,135 $ 2,633 Level 3 Inputs For assets or liabilities for which the Company is required to remeasure the fair value on a recurring basis at each reporting date, generally the Company is required to disclose certain quantitative data related to the inputs used at the most recent reporting period date. However, for those assets or liabilities for which the Company has elected to take the FVO in accordance with ASC 825, Financial Instruments , then such quantitative disclosures are not required. Liability Classified Warrants The liability classified warrants as of March 31, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of March 31, 2024 and December 31, 2023. March 31, 2024 Minimum Maximum Expected volatility 85.00 % 100.00 % Equivalent term (#) 3.58 5.25 Risk-free rate 4.26 % 4.35 % Dividend yield 0.00 % 0.00 % Stock price $ 0.73 $ 0.73 Strike price (#) $ 0.20 $ 11.50 December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 0.44 $ 0.44 Strike price $ 0.50 $ 11.50

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes In accordance with U.S. GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The Company’s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. The Company believes its tax filing position and deductions related to tax periods subject to examination will be sustained under audit and, therefore, has no reserve for uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 12. Net Loss Per Share The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended March 31, 2024 2023 Net loss $ ( 12,697 ) $ ( 7,096 ) Weighted-average shares outstanding - basic and diluted 67,106,081 13,025,852 Basic and diluted net loss per share $ ( 0.19 ) $ ( 0.54 ) The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of March 31, 2024 2023 Investor D warrants 3,158,086 328,352 Investor E warrants 16,261,142 — Placement Agent warrants 542,038 — Public Stockholders' warrants 10,550,000 10,350,000 Private Placement warrants 5,738,000 5,738,000 PIPE Investor warrants 500,000 700,000 Legacy warrants 48,914 69,714 Employee based options to purchase common stock 213,273 244,792 Unvested employee based restricted stock units 306,772 298,389 Total 37,318,225 17,729,247

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events Investor D April 2024 Side Letter On April 1, 2024, the Company and Investor D entered into the a side letter agreement (the "April 2024 Side Letter") whereby each party agreed to suspend certain rights of Investor D for a 60 day period, extending those rights from March 30, 2024, to May 30, 2024. Those rights included a 10 day notice period for any subsequent financing and rights to review terms of such financing arrangements. Finally, Investor D waived its rights or notice of default in the event of such financings. In addition, after the end to the May 30, 2024, suspension period has been reached, Investor D has the right to require the Company to redeem all or a portion of any outstanding Investor D convertible notes in the amount equity to 200 % of the conversion amount.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Use of Estimates	Use of estimates The preparation of the unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates include the valuation of the liability classified warrants, prepaid forward purchase agreement derivative liability, provision for income taxes, convertible debt measured at fair value, and the amount of stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management's best judgments at the time.
Concentrations of credit risk	Concentrations of credit risk Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company's financial condition, results of operations, and cash flows.
Fair value of financial instruments	Fair value of financial instruments The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statement of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date. The Company uses a Black-Scholes option pricing model to fair value Warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is an interpolated value based on the remaining term of each individual instrument. The change in fair value of the liability classified warrants each reporting period is recorded to the change in fair value of warrants liability in the consolidated statement of operations.
Emerging growth company status	Emerging growth company status The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
Recently issued accounting standards	Recently issued accounting standards In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures . ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. We are currently assessing the impact of this guidance on our disclosures.

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Liabilities, Current [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following amounts as of March 31, 2024 and December 31, 2023: ($ in thousands) March 31, December 31, Accrued bonus $ 671 $ 501 Accrued director compensation 519 427 Accrued research and development 308 507 Accrued legal — 43 Accrued interest 29 19 Other 17 26 Total accrued expenses $ 1,544 $ 1,523

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Payable [Abstract]
Summary of Notes Payable	Notes payable activity was as follows for the three month period ended March 31, 2024: ($ in thousands) LMFA LMFAO Maxim Insurance Financing Unamortized deferred financing costs Balance as of December 31, 2023 $ 296 $ 1,128 $ 2,771 $ 565 $ ( 52 ) Payments ( 296 ) ( 1,128 ) ( 181 ) ( 208 ) — Amortization of costs — — — — 27 Balance as of March 31, 2024 $ — $ — $ 2,590 $ 357 $ ( 25 )
Schedule of Future Maturities of Principal Repayment of Convertible Notes	Future maturities of principal repayment of the notes payable as of March 31, 2024 are as follows: ($ in thousands) 2024 (remaining) $ 357 2025 2,590 $ 2,947

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Instrument [Line Items]
The Activity for the Convertible Notes	The activity for the convertible notes is disclosed in the table below for the period ended March 31, 2024. ($ in thousands) 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 3rd Investor D Note 4th Investor D Note 5th Investor D Note 6th Investor D Note Total Balance as of December 31, 2023 $ 1,012 999 $ 972 $ 568 $ 822 $ — $ — $ 4,373 Issuance (Face Value) — — — — — 272 815 1,087 Fair value of detachable warrants at issuance — — — — — ( 147 ) ( 439 ) ( 586 ) (Gain)/Loss on conversion 1,201 636 615 381 77 482 2,005 5,397 Conversion to common stock ( 2,213 ) ( 1,635 ) ( 1,587 ) ( 949 ) ( 125 ) ( 607 ) ( 2,381 ) ( 9,497 ) (Gain)/Loss on reporting period remeasurement — — — — 361 — — 361 Balance as of March 31, 2024 $ — — $ — $ — $ 1,135 $ — $ — 1,135
Convertible Notes [Member]
Debt Instrument [Line Items]
Future Maturities of Principal Repayment of Convertible Notes	Future maturities of principal repayment of convertible Notes as of March 31, 2024, was as follows: ($ in thousands) 2024 (remaining) $ — 2025 1,135 $ 1,135

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrants Outstanding	The Company had the following warrants outstanding at March 31, 2024 and December 31, 2023: March 31, December 31, Liability Classified Warrants Investor D Warrants 3,158,086 6,368,289 Private Placement Warrants 5,738,000 5,738,000 PIPE Investor Warrants 500,000 500,000 Subtotal 9,396,086 12,606,289 Equity Classified Warrants Investor E Warrants 16,261,142 — Placement agent Warrants 542,038 — Public Stockholders' Warrants 10,550,000 10,550,000 Legacy Warrants 48,914 48,914 Subtotal 27,402,094 10,598,914 Grand Total 36,798,180 23,205,203
Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche	The following tables provides the weighted-average strike price and time to maturity for each warrant tranche as of March 31, 2024 and December 31, 2023: March 31, 2024 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Investor D Warrants 3,158,086 $ 0.50 4.40 Private Placement Warrants 5,738,000 $ 11.50 3.57 PIPE Investor Warrants 500,000 $ 11.50 3.57 Equity Classified Warrants Investor E Warrants 16,261,142 $ 0.83 4.45 Placement Agent Warrants 542,038 $ 0.91 5.25 Public Stockholders' Warrants 10,550,000 $ 11.50 3.57 Legacy SeaStar Inc. Warrants 48,914 $ 10.00 2.13 December 31, 2023 Warrant Share Equivalents Weighted-Average Strike Price Weighted-Average Time to Maturity Liability Classified Warrants Investor D Warrants 6,368,289 $ 0.50 4.65 Private Placement Warrants 5,738,000 $ 11.50 3.82 PIPE Investor Warrants 500,000 $ 11.50 3.82 Equity Classified Warrants Public Stockholders' Warrants 10,550,000 $ 11.50 3.82 Legacy SeaStar Inc. Warrants 48,914 $ 10.00 2.38
Schedule of Warrant Activity	Below is the warrant activity for the period ended March, 31, 2024: Investor D Warrants Investor E Warrants Placement Agent Warrants Private Placement Warrants PIPE Investor Warrants Public Stockholders' Warrants Legacy Warrants Outstanding as of December 31, 2023 6,368,289 — - 5,738,000 500,000 10,550,000 48,914 Issuance 1,055,416 20,797,358 542,038 — — — — Exercised ( 4,265,619 ) ( 4,536,216 ) — — — — — Forfeited / cancelled — — — — — — — Outstanding as of March 31, 2024 3,158,086 16,261,142 542,038 5,738,000 500,000 10,550,000 48,914

Stock-Based Compensation Awar_2

Stock-Based Compensation Awards (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-based Compensation Expense	The following table sets forth the total stock-based compensation cost included in the Company's condensed consolidated statements of operations for the period indicated: Hi, I am hiring for my 9* logistics company. If interested, please send working stats and # of EE merits. Thank you! Three Months Ended March 31, ($ in thousands) 2024 2023 Research and development $ 119 $ 39 General and administrative 315 466 Total stock-based compensation $ 434 $ 505
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2022 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding at December 31, 2023 351,029 $ 1.84 $ — 9.1 Exercised — Issued — Forfeited / cancelled — Outstanding at March 31, 2024 351,029 $ 1.84 $ — 8.8 Vested and exercisable at March 31, 2024 - $ — $ — 8.8
Summary of RSU Activity	A summary of the Company’s restricted stock unit (‘RSU”) activity is as follows: 2022 Omnibus Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding at December 31, 2023 234,019 $ 1.47 Granted — Vested — Forfeited / cancelled — Outstanding at March 31, 2024 234,019 $ 1.47
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Option activity	2019 Omnibus Incentive Plan - Options Options Weighted-Average Exercise Price Total Intrinsic Value Weighted-Average Remaining Contractual Life (Years) Outstanding at December 31, 2023 244,792 $ 1.84 $ — 6.4 Exercised — Issued — Forfeited / cancelled — Outstanding at March 31, 2024 244,792 $ 1.84 $ — 6.2 Vested and exercisable at March 31, 2024 213,273 $ 1.84 $ — 6.2
Summary of RSU Activity	2019 Stock Incentive Plan - RSUs Number of RSU Weighted-Average Grand Date Fair Value (per share) Outstanding at December 31, 2023 92,442 $ 8.00 Exercised — Vested ( 19,689 ) Forfeited / cancelled — Outstanding at March 31, 2024 72,753 $ 8.00

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company's financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of March 31, 2024 and December 31, 2023, by level withing the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment. Fair Value Measurements at March 31, 2024 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 1,135 $ 1,135 Liability classified warrants — — 2,633 2,633 $ — $ — $ 3,768 $ 3,768 Fair Value Measurements at December 31, 2023 (Level 1) (Level 2) (Level 3) Total Liabilities: Convertible notes $ — $ — $ 4,179 $ 4,179 Liability classified warrants — — 2,307 2,307 Total $ — $ — $ 6,486 $ 6,486
Summary of Changes in Forward Option and Convertible Notes Derivative Liability	The following table presents the changes in the forward option-prepaid forward contracts, convertible notes measured at fair value, warrants liability, and the notes derivative liability for the periods ended March 31, 2024 and December 31, 2023 (in thousands): Level 3 Roll Forward Convertible Notes Liability Classified Warrants Balance December 31, 2023 $ 4,373 $ 2,307 Additions 501 586 Cash paid to settle — — Shares issued upon conversion or exercise ( 4,100 ) ( 3,106 ) Changes in fair value 361 2,846 Balance March 31, 2024 $ 1,135 $ 2,633
Schedule of Significant Assumptions Valuing of Fair Value	The liability classified warrants as of March 31, 2024 and December 31, 2023, include three classes of warrants, and therefore, the range of assumptions used has been provided. Significant assumptions used in valuing warrants which require liability classification were as follows as of March 31, 2024 and December 31, 2023. March 31, 2024 Minimum Maximum Expected volatility 85.00 % 100.00 % Equivalent term (#) 3.58 5.25 Risk-free rate 4.26 % 4.35 % Dividend yield 0.00 % 0.00 % Stock price $ 0.73 $ 0.73 Strike price (#) $ 0.20 $ 11.50 December 31, 2023 Minimum Maximum Expected volatility 85.00 % 90.00 % Equivalent term 4.04 4.65 Risk-free rate 3.84 % 3.90 % Dividend yield 0.00 % 0.00 % Stock price $ 0.44 $ 0.44 Strike price $ 0.50 $ 11.50

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2024
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Shares	The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive: As of March 31, 2024 2023 Investor D warrants 3,158,086 328,352 Investor E warrants 16,261,142 — Placement Agent warrants 542,038 — Public Stockholders' warrants 10,550,000 10,350,000 Private Placement warrants 5,738,000 5,738,000 PIPE Investor warrants 500,000 700,000 Legacy warrants 48,914 69,714 Employee based options to purchase common stock 213,273 244,792 Unvested employee based restricted stock units 306,772 298,389 Total 37,318,225 17,729,247
Summary of Weighted Average Shares Outstanding for Basic and Diluted Net Loss Per Share	The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information): Three Months Ended March 31, 2024 2023 Net loss $ ( 12,697 ) $ ( 7,096 ) Weighted-average shares outstanding - basic and diluted 67,106,081 13,025,852 Basic and diluted net loss per share $ ( 0.19 ) $ ( 0.54 )

Description of Business - Addit

Description of Business - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 127,431	$ 114,734
Cash	$ 5,019	$ 176

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued bonus	$ 671	$ 501
Accrued director compensation	519	427
Accrued research and development	308	507
Accrued legal	0	43
Accrued interest	29	19
Other	17	26
Total accrued expenses	$ 1,544	$ 1,523

Notes Payable - Summary of Note

Notes Payable - Summary of Notes payable (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Notes Payable [Line Items]
Payments	$ (1,813)	$ (2,596)
Unamortized deferred financing costs, Balance	(52)
Amortization of costs	27	$ 4
Unamortized deferred financing costs, Balance	(25)
Total	1,135		$ 4,373
LMFA [Member]
Notes Payable [Line Items]
Notes payable, Balance	296
Payments	(296)
LMFAO [Member]
Notes Payable [Line Items]
Notes payable, Balance	1,128
Payments	(1,128)
Maxim [Member]
Notes Payable [Line Items]
Notes payable, Balance	2,771
Payments	(181)
Notes payable, Balance	2,590
Insurance Financing [Member]
Notes Payable [Line Items]
Notes payable, Balance	565
Payments	(208)
Notes payable, Balance	$ 357

Notes Payable - Future Maturiti

Notes Payable - Future Maturities of Principal Repayment of Convertible Notes (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Notes Payable [Abstract]
2024 (remaining)	$ 357
2025	2,590
Total	$ 2,947

Notes Payable - Senior Secured

Notes Payable - Senior Secured LMFA Notes Payable - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Notes Payable [Line Items]
Cash proceeds	$ 0	$ 100
Senior Secured LMFA Notes Payable [Member]
Notes Payable [Line Items]
Debt instrument, interest rate	7%
Debt instrument, maturity date	Mar. 27, 2025

Notes Payable - Senior Secure_2

Notes Payable - Senior Secured LMFAO Note Payable - Additional Information (Details) - Senior Secured LMFAO Note Payable [Member]	3 Months Ended
	Mar. 31, 2024
Notes Payable [Line Items]
Debt instrument, maturity date	Mar. 27, 2025
Debt instrument, interest rate	7%

Notes Payable - Unsecured Maxim

Notes Payable - Unsecured Maxim Note Payable - Additional Information (Details) - Unsecured Maxim Note Payable [Member] $ in Millions	1 Months Ended
	Oct. 31, 2022 USD ($)
Notes Payable LineItems
Professional fees	$ 4.2
Debt instrument, interest rate	7%
Debt instrument, maturity date	May 08, 2025

Notes Payable - Insurance Finan

Notes Payable - Insurance Financing - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2023	Mar. 31, 2024	Dec. 31, 2023
Notes Payable [Line Items]
Annual premium of insurance policy amount	$ 700
Frequency of principal and interest payments		monthly
Payment terms		The Company will pay the remaining five monthly installments of principal and interest with the last payment being made in August 2024
Insurance Financing [Member]
Notes Payable [Line Items]
Notes payable, gross		$ 357	$ 565

Convertible Notes - Activity fo

Convertible Notes - Activity for the Convertible Notes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Debt Instrument [Line Items]
Balance	$ 4,373
Issuance (Face Value)	1,087
Fair value of detachable warrants at issuance	2,846	$ (36)
(Gain)/Loss on conversion	5,397
Conversion to common stock	(9,497)
(Gain)/Loss on reporting period remeasurement	361
Balance	1,135
Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	(586)
3rd Investor D Note 3-1
Debt Instrument [Line Items]
Balance	1,012
Issuance (Face Value)	0
(Gain)/Loss on conversion	1,201
Conversion to common stock	(2,213)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
3rd Investor D Note 3-1 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	0
3rd Investor D Note 3-2
Debt Instrument [Line Items]
Balance	999
Issuance (Face Value)	0
(Gain)/Loss on conversion	636
Conversion to common stock	(1,635)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
3rd Investor D Note 3-2 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	0
3rd Investor D Note 3-3
Debt Instrument [Line Items]
Balance	972
Issuance (Face Value)	0
(Gain)/Loss on conversion	615
Conversion to common stock	(1,587)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
3rd Investor D Note 3-3 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	0
3rd Investor D Note 3-4
Debt Instrument [Line Items]
Balance	568
Issuance (Face Value)	0
(Gain)/Loss on conversion	381
Conversion to common stock	(949)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
3rd Investor D Note 3-4 | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	0
4th Investor D Note
Debt Instrument [Line Items]
Balance	822
Issuance (Face Value)	0
(Gain)/Loss on conversion	77
Conversion to common stock	(125)
(Gain)/Loss on reporting period remeasurement	361
Balance	1,135
4th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	0
5th Investor D Note
Debt Instrument [Line Items]
Balance	0
Issuance (Face Value)	272
(Gain)/Loss on conversion	482
Conversion to common stock	(607)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
5th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	(147)
6th Investor D Note
Debt Instrument [Line Items]
Balance	0
Issuance (Face Value)	815
(Gain)/Loss on conversion	2,005
Conversion to common stock	(2,381)
(Gain)/Loss on reporting period remeasurement	0
Balance	0
6th Investor D Note | Convertible Debt Securities
Debt Instrument [Line Items]
Fair value of detachable warrants at issuance	$ (439)

Convertible Notes - Future Matu

Convertible Notes - Future Maturities of Principal Repayment of Convertible Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total	$ 1,135	$ 4,373
Convertible Notes [Member]
Debt Instrument [Line Items]
2024 (remaining)	0
2025	1,135
Total	$ 1,135

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Jan. 30, 2024	Jan. 24, 2024	Jan. 12, 2024	Mar. 31, 2024	Mar. 31, 2023	Jan. 26, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Initial conversion price		$ 0.56
Common stock, par value			$ 0.0001	$ 0.0001			$ 0.0001
Warrant exercise price				$ 0.9132
Additional warrants to purchase						542,038
Loss on extinguishment of convertible notes				$ 5,800
Loss on coversion into equity				4,700
Conversion of outstanding debt to common stock				9,497
Change in fair value of convertible notes				(5,758)	$ 100
Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issuing notes in principal amounts		$ 800	$ 300
Initial conversion price			$ 0.56
Interest rate of senior unsecured convertible note issued		7%	7%
Maturity date		Apr. 24, 2025	Apr. 12, 2025
Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issued warrants to purchase		395,781,000
Warrant exercise price		$ 0.56	$ 0.56
Additional warrants to purchase		395,781,000
Maximum [Member] | Common Stock [Member] | Investor D Convertible Notes And Warrant Activity [Member]
Debt Instrument [Line Items]
Issued warrants to purchase			131,927,000
Additional warrants to purchase			131,927,000
Convertible Notes [Member] | Investor Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount				1,000
Optional debt redemption rights suspension period	60 days
Debt redemption percentage	200%
Debt conversion, original debt amount				3,300
Conversion of outstanding debt to common stock				9,500
Fair value of convertible notes				1,100
Investor D Convertible Notes [Member]
Debt Instrument [Line Items]
Losses on issuance of the convertible notes				700
Conversion of outstanding debt to common stock				$ 400

Equity Transactions - Additiona

Equity Transactions - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	Jan. 26, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrant exercise price		$ 0.9132
Warrants to purchase Common stock	542,038
Warrants issued fair value	$ 300
Placement agent fee paid		$ 700
Warrant exerciseable date		Jan. 30, 2024
Proceeds from issuance of shares		$ 4,543	$ 1,108
Amount available to draw				$ 95,300
Tumim Stone Capital [Member]
Class of Warrant or Right [Line Items]
Shares issued				6,500,000
Proceeds from issuance of shares				$ 4,700
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.0001
Warrants to purchase Common stock	6,304,545
Aggregate gross proceeds	$ 9,000
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.8302
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	10,840,761
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock	5,420,381
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price	$ 0.0001
Warrants to purchase Common stock	4,536,216

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Jan. 26, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			542,038
Warrants initial exercise price	$ 0.9132
Fair value of detachable warrants at issuance	$ 2,846	$ (36)
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Fair value of detachable warrants at issuance	$ 1,200
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			6,304,545
Warrants initial exercise price			$ 0.0001
Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price			$ 0.8302
Pre-funded Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			4,536,216
Warrants initial exercise price			$ 0.0001
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock from total shares percentage	5%
Warrants exercisable at price equal to offering price percentage	110%
Private Placement Warrants [Member] | Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price	$ 11.5			$ 11.5
Series A Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			10,840,761
Series B Warrants [Member] | Common Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase Common stock			5,420,381
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Loss on exercises	$ 1,600
Investor D Warrants [Member] | Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants initial exercise price	$ 0.5			$ 0.5

Warrants - Schedule of Warrants

Warrants - Schedule of Warrants Outstanding (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 36,798,180	$ 23,205,203
Liability Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	9,396,086	12,606,289
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	3,158,086	6,368,289
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	5,738,000	5,738,000
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	500,000	500,000
Equity Classified Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	27,402,094	10,598,914
Equity Classified Warrants [Member] | Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	16,261,142	0
Equity Classified Warrants [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	542,038	0
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	10,550,000	10,550,000
Equity Classified Warrants [Member] | Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	$ 48,914	$ 48,914

Warrants - Schedule of Weighted

Warrants - Schedule of Weighted-Average Strike Price and Time to Maturity for Each Warrant Tranche (Details) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Weighted-Average Strike Price	$ 0.9132
Liability Classified Warrants [Member] | Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	3,158,086	6,368,289
Weighted-Average Strike Price	$ 0.5	$ 0.5
Weighted-Average Time to Maturity	4 years 4 months 24 days	4 years 7 months 24 days
Liability Classified Warrants [Member] | Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	5,738,000	5,738,000
Weighted-Average Strike Price	$ 11.5	$ 11.5
Weighted-Average Time to Maturity	3 years 6 months 25 days	3 years 9 months 25 days
Liability Classified Warrants [Member] | PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	500,000	500,000
Weighted-Average Strike Price	$ 11.5	$ 11.5
Weighted-Average Time to Maturity	3 years 6 months 25 days	3 years 9 months 25 days
Equity Classified Warrants [Member] | Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	16,261,142
Weighted-Average Strike Price	$ 0.83
Weighted-Average Time to Maturity	4 years 5 months 12 days
Equity Classified Warrants [Member] | Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	542,038
Weighted-Average Strike Price	$ 0.91
Weighted-Average Time to Maturity	5 years 3 months
Equity Classified Warrants [Member] | Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	10,550,000	10,550,000
Weighted-Average Strike Price	$ 11.5	$ 11.5
Weighted-Average Time to Maturity	3 years 6 months 25 days	3 years 9 months 25 days
Equity Classified Warrants [Member] | Legacy SeaStar Inc. Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Share Equivalents	48,914	48,914
Weighted-Average Strike Price	$ 10	$ 10
Weighted-Average Time to Maturity	2 years 1 month 17 days	2 years 4 months 17 days

Warrants - Schedule of Warrant

Warrants - Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2024 shares
Investor D Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	6,368,289
Issuance	1,055,416
Exercised	(4,265,619)
Forfeited/cancelled	0
Outstanding Balance	3,158,086
Investor E Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	20,797,358
Exercised	(4,536,216)
Forfeited/cancelled	0
Outstanding Balance	16,261,142
Placement Agent warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	0
Issuance	542,038
Exercised	0
Forfeited/cancelled	0
Outstanding Balance	542,038
Private Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	5,738,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Outstanding Balance	5,738,000
PIPE Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	500,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Outstanding Balance	500,000
Public Stockholders Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	10,550,000
Issuance	0
Exercised	0
Forfeited/cancelled	0
Outstanding Balance	10,550,000
Legacy Warrants [Member]
Class of Warrant or Right [Line Items]
Outstanding Balance	48,914
Issuance	0
Exercised	0
Forfeited/cancelled	0
Outstanding Balance	48,914

Stock-Based Compensation Awar_3

Stock-Based Compensation Awards - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 434	$ 505
Research and Development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	119	39
General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 315	$ 466

Stock-Based Compensation Awar_4

Stock-Based Compensation Awards - Additional Information (Details) - Key Employees and Non-Employee Service Providers [Member] - 2022 Omnibus Incentive Plan [Member]	3 Months Ended
	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options expiration period	10 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years

Stock-Based Compensation Awar_5

Stock-Based Compensation Awards - Summary of Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	351,029,000
Exercised	0
Issued	0
Forfeited / cancelled	0
Ending balance, Outstanding	351,029,000	351,029,000
Vested and exercisable	0
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 1.84
Ending balance, Outstanding	1.84	$ 1.84
Vested and exercisable	$ 0
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	8 years 9 months 18 days	9 years 1 month 6 days
Vested and exercisable	8 years 9 months 18 days
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance, Outstanding	244,792,000
Exercised	0
Issued	0
Forfeited / cancelled	0
Ending balance, Outstanding	244,792,000	244,792,000
Vested and exercisable	213,273
Weighted Average Exercise Price
Beginning balance, Outstanding	$ 1.84
Ending balance, Outstanding	1.84	$ 1.84
Vested and exercisable	$ 1.84
Total Intrinsic Value
Outstanding	$ 0	$ 0
Vested and exercisable	$ 0
Weighted Average Remaining Contractual Life (Years)
Outstanding	6 years 2 months 12 days	6 years 4 months 24 days
Vested and exercisable	6 years 2 months 12 days

Stock-Based Compensation Awar_6

Stock-Based Compensation Awards - Summary of RSU Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares shares
2022 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	234,019
Granted	0
Vested	0
Forfeited / cancelled	0
Ending Balance, Outstanding	234,019
Beginning Balance, Outstanding | $ / shares	$ 1.47
Ending Balance, Outstanding | $ / shares	$ 1.47
2019 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Beginning Balance, Outstanding	92,442
Exercised	0
Vested	(19,689)
Forfeited / cancelled	0
Ending Balance, Outstanding	72,753
Beginning Balance, Outstanding | $ / shares	$ 8
Ending Balance, Outstanding | $ / shares	$ 8

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
	Jan. 03, 2023	Dec. 27, 2022	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Loss Contingencies [Line Items]
Legal settlement in accrued expenses			$ 200
Rent expense				$ 8	$ 8
Upfront payment liability			100	$ 100
License and Distribution Agreement [Member]
Loss Contingencies [Line Items]
Proceeds from upfront payment	$ 100
Proceeds from milestone payment		$ 400
Agreement term		3 years
Amended License and Distribution Agreement [Member]
Loss Contingencies [Line Items]
Nonrefundable upfront payment			$ 100
Humanitarian Device Approval ("HDE") from FDA [Member] | License and Distribution Agreement [Member]
Loss Contingencies [Line Items]
Proceeds from milestone payment		$ 500

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 3,768	$ 6,486
Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1,135	4,179
Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	2,633	2,307
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 1 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 2 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	0	0
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	3,768	6,486
Level 3 [Member] | Convertible Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	1,135	4,179
Level 3 [Member] | Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities	$ 2,633	$ 2,307

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Changes in Forward Option and Convertible Notes Derivative Liability (Detail) - Level 3 [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 4,373
Additions	501
Cash paid to settle	0
Shares issued upon conversion or exercise	(4,100)
Changes in fair value	361
Balance	1,135
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	2,307
Additions	586
Cash paid to settle	0
Shares issued upon conversion or exercise	(3,106)
Changes in fair value	2,846
Balance	$ 2,633

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Significant Assumptions Valuing of Fair Value (Details) - Warrants [Member]	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.0435	0.039
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.0426	0.0384
Expected Volatility [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	1	0.90
Expected Volatility [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.85	0.85
Equivalent Term [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	5 years 3 months	4 years 7 months 24 days
Equivalent Term [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equivalent term	3 years 6 months 29 days	4 years 14 days
Dividend Yield [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0	0
Dividend Yield [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0	0
Stock Price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.0073	0.0044
Stock Price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.0073	0.0044
Strike price [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.115	0.115
Strike price [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.002	0.005

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share Basic And Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Earnings Per Share [Abstract]
Net loss	$ (12,697)	$ (7,096)
Weighted-average shares outstanding - basic	67,106,081	13,025,852
Basic net loss per share	$ (0.19)	$ (0.54)
Weighted-average shares outstanding - diluted	67,106,081	13,025,852
Diluted net loss per share	$ (0.19)	$ (0.54)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Weighted-Average Outstanding Shares (Detail) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	37,318,225	17,729,247
Investor D Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,158,086	328,352
Investor E Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	16,261,142	0
Placement Agent warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	542,038	0
Public Stockholders Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	10,550,000	10,350,000
Private Placement Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,738,000	5,738,000
PIPE Investor Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	500,000	700,000
Legacy (Pre-merger) Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	48,914	69,714
Employee Based Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	213,273	244,792
Unvested Employee Based Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	306,772	298,389

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event [Member]	Apr. 01, 2024
Subsequent Event [Line Items]
Percentage of conversion amount	200%
Suspention period	60 days
Investment right notice period	10 days